NEW YORK, April 15 /PRNewswire-FirstCall/ -- Enhance Biotech, Inc. (BULLETIN BOARD: EBOI) , a developer of a portfolio of products focused on lifestyle drugs, today announced that it has teamed with SoleRx LLC, a developer, consultant and advisor on proprietary therapeutic candidates for dermatology and inflammation, to advance the development of products in Enhance Biotech's EBOI, LI 412 group of treatments for urticaria and itch.
Enhance Biotech is in the process of developing a dermatology and skin care portfolio of products that include treatments for moderate to severe atopic dermatitis, psoriasis, eczema and allergy itch, cellulite and gum disorders. This portfolio of prescription products under development are expected to reach the market phased over the next thirty-six months and should position the Company as a leading player in the area of skincare.
The scientific founders of SoleRx are Seth Orlow, MD, PhD and Seth Lederman, MD. Dr. Orlow is a professor of Dermatology, Cell Biology and Pediatrics at New York University School of Medicine and was a co-founder of Anaderm Research Corporation, a dermatology drug discovery company that was acquired in 2002 by Pfizer. Dr. Lederman is associate professor of Medicine at Columbia Medical School and was a co-founder of the specialty pharmaceutical companies, Vela and Targent.
Chris Every, CEO of Enhance commented, "I am delighted to be able to announce the formalization of our relationship at this time, as we have now been able to define and target the development of some unique applications. The scientific and development experience SoleRx brings to Enhance will significantly benefit Enhance in its development objectives of introducing drugs in the LI 412 family to market quickly and effectively."
About Enhance Biotech
Enhance Biotech Inc. is developing a product portfolio focused upon two key areas of lifestyle drug development: Male Sexual Dysfunction and clinical Skin Care indications. Within those two areas the key conditions are: Sexual Dysfunctions, including Premature Ejaculation and Male Fertility and Skincare Indications, including Periodontal Disease, Cellulite, Anti-aging and Dermatological Disorders covering Atopic Dermatitis to Psoriasis. Enhance's products are licensed in at pre-clinical or Phase I stages and are being taken through development and approval to market mainly through targeted licensing partnerships for each product, adding significant value to each in the process. This creates a valuable product pipeline portfolio in a lifestyle market forecast at conservative estimates to grow to US$32 billion by 2008. The pharmaceutical industry has invested over $20 billion in R&D for lifestyle drugs in the last ten years, although relatively few new products have as yet reached the market. Enhance's lead development products fill unmet needs in global blockbuster markets. The Management and Science Team have a proven track record of successful development and commercialization of new products and the licensing out of valuable intellectual property. For more information on the Company please see the Company's website at http://www.enhancelifesciences.com/ .
SoleRx develops proprietary therapeutic candidates for dermatology and inflammation. SoleRx also provides consulting and advisory services on strategy, drug development and partnering. The SoleRx approach to innovation is based on first identifying "disease targets" (unmet needs for target indications), and then exploiting knowledge of the disease's pathogenesis to find a pathway in which a drug can intervene. The efficiency of its approach is enhanced by SoleRx's understanding of what drives the disease process and what type of therapy would be a clinically significant addition to the pharmacopoeia. For more information, please contact info@SoleRx.com.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Biotech's compounds under development in particular; the potential failure of Enhance Biotech's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Biotech's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Biotech's business, structure or projections; the development of competing products; uncertainties related to Enhance Biotech's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under the Company's prior name Becor Communications, Inc. The Company and Enhance Biotech disclaim any obligation to update these forward-looking statements.
European Contact: Investor Contact:
John Gisborne Laurel Moody
Splash Communications Sky Investor Relations
(44) 1225 - 318000 212-440-5000
Enhance Biotech, Inc.